Skin, soft tissue, ENT, respiratory tract and other infections due to Gram-positive organisms (including beta lactamase producing staphylococci and streptococci).
Flucloxacillin is indicated for the treatment of infections caused by susceptible bacteria. Specific approved indications include:
Staphylococcal skin infections and cellulitis – including impetigo, otitis externa, folliculitis, boils, carbuncles, and mastitis
Osteomyelitis, septic arthritis
Empirical treatment for endocarditis
Flucloxacillin has relatively poor activity against non-β-lactamase-producing bacteria including Streptococcus pyogenes. Therefore, empirical therapy for significant cellulitis often involves dual-therapy to cover both staphylococci and streptococci, using either penicillin orampicillin in addition to flucloxacillin.
Bactericidal; inhibit bacterial cell wall synthesis. Action is dependent on the ability of penicillins to reach and bind penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall.
PBPs (which include transpeptidases, carboxypeptidases, and endopeptidases) are enzymes that are involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Penicillins bind to, and inactivate, PBPs, resulting in the weakening of the bacterial cell wall and lysis